Instil Bio to Present at Jefferies Cell and Genetic Medicine Summit
Instil Bio, Inc. (Nasdaq: TIL), a clinical-stage biopharmaceutical company specializing in tumor infiltrating lymphocyte (TIL) therapies, will participate in the Jefferies Cell and Genetic Medicine Summit on September 29, 2022, at 10:30 a.m. ET. This event includes a company presentation and Q&A session. Investors can access a live webcast of the presentation under the 'News & Events' section on the company's website. Instil is developing therapies for advanced melanoma and other solid tumors, leveraging its proprietary manufacturing processes for its lead product candidate, ITIL-168.
- None.
- None.
DALLAS, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company management will participate in an upcoming investor conference:
Jefferies Cell and Genetic Medicine Summit
Company presentation and Q&A: Thursday, September 29, 2022 at 10:30 a.m. ET
A live webcast, if recorded, of the presentation can be accessed under “News & Events” in the Investors section of the Company’s website at www.instilbio.com. The archived webcast will be available on the Company’s website shortly after the event.
About Instil Bio
Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or (TIL), therapies for the treatment of patients with cancer. The Company has assembled an accomplished management team with a successful track record in the development, manufacture, and commercialization of cell therapies. Using the Company’s proprietary, optimized, and scalable manufacturing processes at its in-house manufacturing facilities, Instil is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma and other solid tumors as well as ITIL-306, a next-generation, genetically engineered TIL therapy for multiple solid tumors. For more information visit www.instilbio.com and LinkedIn.
Contacts:
Investor Relations
1-972-499-3350
investorrelations@instilbio.com
www.instilbio.com
Janhavi Mohite
Stern Investor Relations
1-212-362-1200
janhavi.mohite@sternir.com
FAQ
When is Instil Bio participating in the Jefferies Cell and Genetic Medicine Summit?
What is the focus of Instil Bio's therapies?
How can investors access the presentation from Instil Bio?
What is ITIL-168?
What other product candidates is Instil Bio developing?
